Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HRH1 | P35367 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | CASR | P41180 | 1/20 | 0.30 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5929248 | 0.89 | KDM4E (0.33) | KDM4EALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL5928992 | 0.89 | CYP3A4 (0.36) | KDM4EALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL5929127 | 0.86 | ALDH1A1 (0.35) | KDM4EALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL5929181 | 0.86 | KMT2A (0.34) | KDM4EALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL5928890 | 0.83 | KDM4E (0.32) | KDM4EALDH1A1 | |
| SCHEMBL5928969 | 0.83 | HCRTR1 (0.37) | KDM4EALDH1A1 | |
| SCHEMBL5929118 | 0.83 | KMT2A (0.36) | KDM4EALDH1A1KMT2ANPSR1 | |
| SCHEMBL5929060 | 0.77 | CYP3A4 (0.36) | KDM4EALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL5929125 | 0.76 | GAA (0.40) | KDM4EALDH1A1KMT2ATSHRSMN1; SMN2 | |
| SCHEMBL5929178 | 0.76 | OPRK1 (0.39) | KDM4EALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060154917-A1 | Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators | NEUROGEN CORPORATION (US) | 2006-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154917-A1 | Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators | C5AR1, C5AR2, C3AR1 | KDM4E 1762/4885ALDH1A1 3884/4885MEN1 2791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.